Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Planet Green halted again, now up 793%
• Super Micro Computer (SMCI) call put ratio 3.1 calls to 1 put with a focus on August 14 weekly 32 calls into quarter results
• Cooper Cos. (COO) call put ratio 13.5 calls to 1 put with a focus on February 85 calls